Vamorolone Designated Promising Innovative Medicine (PIM) for treatment in Duchenne muscular dystrophy

Rockville, MD, 17 October 2019

In the UK the Early Access to Medicines Scheme (EAMS) is a regulatory path by the MRHA that aims to give patients with life threatening or . . .

Top-line data of 18-month vamorolone treatment of Duchenne muscular dystrophy patients shows continued improvement of symptoms with reduction in corticosteroid safety concerns

Rockville, MD –  5 October 2019
A presentation at the 24th International Annual Congress of the World Muscle Society (WMS) in Copenhagen, Denmark reported top-line data from 18-month treatment of Duchenne muscular dystrophy (DMD) patients (VBP15-LTE trial). 

Vamorolone Treatment of Duchenne Muscular Dystrophy Patients Leads to Improvements in Motor Function

Rockville, MD –  18 August 2019
A publication in the journal Neurology was released today describing efficacy studies of vamorolone, a treatment option being evaluated as a potentially safer alternative to corticosteroids, in boys with Duchenne muscular dystrophy. 

Vamorolone (VBP15) First-in-patient Studies in Duchenne Muscular Dystrophy Published

Rockville, MD –  2 October 2018
A clinical trial of vamorolone in 48 boys with Duchenne muscular dystrophy entitled “Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug” has been More >

ReveraGen Announces First Patient Enrollment in International Pivotal Trial of Vamorolone in Duchenne Muscular Dystrophy

Rockville, MD –  22 August 2018
ReveraGen BioPharma, Inc. today announced the initiation and first patient enrollment in a double-blind, placebo- and prednisone-controlled clinical trial (VBP15-004) of vamorolone, a first-in-class dissociative steroidal anti-inflammatory, in Duchenne muscular dystrophy.

Vamorolone (VBP15) Top Line Data Shows Improvements in Strength and Endurance in Boys with Duchenne Muscular Dystrophy

Rockville, MD – 26 June 2018
Vamorolone (VBP15) Top Line Data Shows Improvements in Strength and Endurance in Boys with Duchenne Muscular Dystrophy.

Finalists Selected – 3rd Annual BioHealth Capital Region Crab Trap Competition

– Winner to be announced during 2018 BioHealth Capital Region Forum –

ROCKVILLE, MARYLAND, April 12, 2018 – Five companies have been selected to present to a panel of investor judges and an audience of industry leaders during the 2018 BioHealth

ReveraGen BioPharma Receives FDA Fast Track Designation for Vamorolone for the Treatment of Duchenne Muscular Dystrophy

ROCKVILLE, Maryland, March 24, 2017

ReveraGen BioPharma Inc, a privately held corporation, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for vamorolone (VBP15) for the treatment of patients with Duchenne muscular dystrophy. This designation

Actelion obtains an option vamorolone from ReveraGen

Vamorolone, a novel compound for the treatment of Duchenne Muscular Dystrophy, holds potential to better preserve muscle function and prolong ambulation for the patient, without some of the side effects associated with glucocorticoid therapy.
ALLSCHWIL, SWITZERLAND, and ROCKVILLE (MD), USA

ReveraGen BioPharma Inc Initiates VISION-DMD Phase 2a Study for Treatment of Duchenne Muscular Dystrophy

Enrollment has begun in the Phase 2a clinical trial of vamorolone (VBP15) in the treatment of boys with Duchenne muscular dystrophy (DMD). The Phase 2a trial sponsored by ReveraGen BioPharma, is an open-label, multiple ascending dose study that will be